Benefits
Stimulant/sympathomimetic effects (animal evidence)
Animal studies in dogs and rats showed hordenine produced a positive inotropic effect on the heart, increased systolic and diastolic BP, and increased peripheral blood flow, via indirect adrenergic activity (norepinephrine release). Critical caveat: effects were short-lived and required high doses, and human translation has not been rigorously demonstrated.
Weak MAO-B inhibitor (potentiates other PEAs)
Hordenine is a selective substrate for MAO-B with weak inhibitory activity. Theoretical mechanism for potentiating phenylethylamine (PEA) and other monoamines that are MAO-B substrates; combined with PEA in some pre-workouts to extend duration. Not a clinically meaningful MAOI like prescription drugs (selegiline, etc.) — far weaker effect.
NO direct lipolytic activity (Haj Ahmed 2021)
A study directly tested hordenine on adipocyte lipolysis and found it does not activate or inhibit lipolysis in fat cells. Adipocytes were responsive to standard stimulants (isoprenaline, forskolin) and inhibitors (insulin) but unresponsive to hordenine. The conclusion was that hordenine is unlikely to increase lipid mobilization from fat depots. Direct evidence against fat-burner marketing claims.
Indirect adrenergic activity (norepinephrine release)
Hordenine acts as indirect adrenergic agonist by promoting norepinephrine release from sympathetic nerve terminals. Mechanism similar to (but weaker than) tyramine and amphetamines. Theoretical contribution to focus and energy through SNS activation — but actual clinical effects in humans are minimal at safe doses.
Bronchodilation (traditional Chinese use)
Used in Traditional Chinese Medicine as 'mao gen' for respiratory conditions including asthma — bronchodilator activity via β-adrenergic indirect effects. Mechanism plausible but rigorous clinical evidence in respiratory conditions absent. Modern bronchodilators (β2-agonists) far more effective.
Mechanism of action
Indirect adrenergic activity via norepinephrine release
Hordenine, like tyramine and amphetamines, is an indirect-acting sympathomimetic — it promotes release of stored norepinephrine from sympathetic nerve terminals. Mechanism does not involve direct receptor binding (unlike epinephrine). Effects depend on existing sympathetic tone and norepinephrine stores. Tachyphylaxis can develop with repeated use.
Selective MAO-B inhibition (weak)
Selectively inhibits MAO-B isoenzyme over MAO-A. In context of PEA potentiation: PEA is rapidly metabolized by MAO-B; hordenine slows this metabolism. However, hordenine itself is also an MAO-B substrate at low concentrations — making it a 'mixed substrate/inhibitor.' Inhibitory activity is weak relative to selective MAOI drugs.
Crosses blood-brain barrier
Lipophilic structure allows penetration into CNS. Theoretically supports nootropic/focus claims, but actual brain levels achieved at oral supplement doses are likely low. CNS effects in humans have not been rigorously characterized via PET imaging or microdialysis studies.
NO direct β-adrenergic agonism in adipocytes
Despite weight loss marketing, hordenine does not bind β-adrenergic receptors directly in adipocytes and cannot stimulate lipolysis directly. Any weight management effects would have to come from indirect mechanisms (general SNS activation), which are modest at safe doses.
Clinical trials
Veterinary pharmacology study (Frank M, Weckman TJ, Wood T, Woods WE, Tai CL, Chang SL, Ewing A, Blake JW, Equine Vet J 22(6):437-441, doi:10.1111/j.2042-3306.1990.tb04313.x).
Horses given oral and intravenous hordenine. Pharmacokinetics (plasma concentration), behavioral effects, vital signs, and respiratory effects measured.
Intravenous administration caused immediate behavioral changes and significant respiratory distress, but symptoms subsided within 30 minutes. Oral administration showed NO noticeable changes — consistent with poor oral bioavailability. Pharmacokinetic analysis revealed rapid plasma clearance, with no lasting stimulant or depressive effects post-dosing. Foundational evidence that oral hordenine produces minimal systemic effects.
Animal pharmacology study (Hapke HJ, Dtsch Tierarztl Wochenschr 102(6):228-232).
Dogs and rats given hordenine orally and intravenously. Cardiovascular, gastrointestinal, and CNS effects assessed; isolated tissue experiments to elucidate mechanism.
Hordenine produced positive inotropic effect, increased BP, increased peripheral blood flow, inhibited GI movements. Effects characterized as indirectly acting adrenergic mechanism via norepinephrine release. Critical caveat: effects were short-lived and required high doses to be observed. Animal findings do not translate directly to human supplement doses.
Adipocyte study (Haj Ahmed W et al. 2021, Integr Food Nutr Metab 8:302).
Mouse fat cells (adipocytes) and human subcutaneous adipose tissue homogenates exposed to hordenine and assessed for lipolytic and antilipolytic responses, plus interaction with monoamine oxidase.
Direct evidence that hordenine does not activate or inhibit lipolysis in adipocytes. Cells were responsive to standard agents (isoprenaline, forskolin, insulin) but unresponsive to hordenine. Confirmed weak MAO interaction (substrate/inhibitor) but no direct fat-cell stimulation. Authors concluded: 'Hordenine consumption cannot likely increase lipid mobilization from fat depots.' Foundational counter-evidence against fat burner marketing claims.